SK9892003A3 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrochloride dihydrate Download PDF

Info

Publication number: SK9892003A3
Authority: SK; Slovakia
Prior art keywords: ondansetron; solution; precipitate; methylcarbazolone; hydrochloride
Prior art date: 2001-01-11

Application number

SK989-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Ramy Lidor Hadas

Eliezer Bachar

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-11

Filing date

2002-01-11

Publication date

2004-05-04

2002-01-11 Application filed by Teva Pharma filed Critical Teva Pharma

2004-05-04 Publication of SK9892003A3 publication Critical patent/SK9892003A3/sk

Links

229960005343 ondansetron Drugs 0.000 title claims abstract description 73
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 title claims abstract description 33
238000004519 manufacturing process Methods 0.000 title claims abstract description 15
238000000034 method Methods 0.000 claims abstract description 58
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims abstract description 41
VHXLDRBDRZYEQE-UHFFFAOYSA-N 3-(dimethylamino)-2-methylcarbazol-1-one Chemical compound C1=CC=C2C3=CC(N(C)C)=C(C)C(=O)C3=NC2=C1 VHXLDRBDRZYEQE-UHFFFAOYSA-N 0.000 claims abstract description 10
238000001953 recrystallisation Methods 0.000 claims abstract description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 37
239000002244 precipitate Substances 0.000 claims description 29
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
238000010438 heat treatment Methods 0.000 claims description 17
XSLBAHVOKAHAJM-UHFFFAOYSA-N 2-methylcarbazol-1-one Chemical compound C1=CC=C2C3=CC=C(C)C(=O)C3=NC2=C1 XSLBAHVOKAHAJM-UHFFFAOYSA-N 0.000 claims description 16
238000002425 crystallisation Methods 0.000 claims description 16
230000008025 crystallization Effects 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 11
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 11
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
229930040373 Paraformaldehyde Natural products 0.000 claims description 9
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 claims description 9
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 claims description 9
XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 claims description 9
229920002866 paraformaldehyde Polymers 0.000 claims description 9
238000005406 washing Methods 0.000 claims description 7
238000001035 drying Methods 0.000 claims description 6
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
238000001556 precipitation Methods 0.000 claims description 4
230000003113 alkalizing effect Effects 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 21
239000002585 base Substances 0.000 description 18
238000002360 preparation method Methods 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
239000006227 byproduct Substances 0.000 description 8
BILTWMIWSIBZNE-UHFFFAOYSA-N 2-[(dimethylamino)methyl]carbazol-1-one Chemical compound C1=CC=C2C3=CC=C(CN(C)C)C(=O)C3=NC2=C1 BILTWMIWSIBZNE-UHFFFAOYSA-N 0.000 description 6
239000012535 impurity Substances 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 4
-1 dimethylamino-methyl-carbazone Chemical compound 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
AGQJDIDJKSFVTC-UHFFFAOYSA-N 9-methyl-3-methylidene-1,2-dihydrocarbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)C(=C)CC2 AGQJDIDJKSFVTC-UHFFFAOYSA-N 0.000 description 3
230000020477 pH reduction Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
102100024954 5-hydroxytryptamine receptor 3A Human genes 0.000 description 1
101710138027 5-hydroxytryptamine receptor 3A Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
235000012970 cakes Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
235000021463 dry cake Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000000622 liquid--liquid extraction Methods 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011085 pressure filtration Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK989-2003A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate SK9892003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26105201P	2001-01-11	2001-01-11
PCT/US2002/000853 WO2002055492A2 (en)	2001-01-11	2002-01-11	An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (1)

Publication Number	Publication Date
SK9892003A3 true SK9892003A3 (en)	2004-05-04

Family

ID=22991757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK989-2003A SK9892003A3 (en)	2001-01-11	2002-01-11	An improved process for preparing pure ondansetron hydrochloride dihydrate

Country Status (21)

Country	Link
EP (1)	EP1355881A4 (cs)
JP (1)	JP2004526692A (cs)
KR (3)	KR20070054749A (cs)
CN (2)	CN101045704A (cs)
AU (1)	AU2002236753B2 (cs)
CA (1)	CA2433720A1 (cs)
CZ (1)	CZ20032090A3 (cs)
DE (1)	DE02703115T1 (cs)
ES (1)	ES2219201T1 (cs)
HR (1)	HRP20030631A2 (cs)
HU (1)	HUP0400767A2 (cs)
IL (1)	IL156835A0 (cs)
IS (1)	IS6869A (cs)
MX (1)	MXPA03006215A (cs)
NO (1)	NO20033147L (cs)
PL (1)	PL368837A1 (cs)
SK (1)	SK9892003A3 (cs)
TR (1)	TR200401460T3 (cs)
WO (1)	WO2002055492A2 (cs)
YU (1)	YU56103A (cs)
ZA (1)	ZA200305338B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE364611T1 (de)	2002-04-29	2007-07-15	Teva Gyogyszergyar Zartkoeruee	Verfahren zur herstellung von 1,2,3,9-tetrahydro- 9-methyl-3- (2-methyl-1h-imidazol-1-yl)methylö- h-carbazol-4-on
HU225885B1 (en) *	2002-10-17	2007-11-28	Richter Gedeon Nyrt	Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) *	2003-01-09	2004-03-15	Synthon Bv	Ondansetronmuotoja
GB2398071B (en) *	2003-01-24	2006-06-07	Synthon Bv	Process for making ondansetron and intermediate thereof
US7696356B2 (en)	2004-08-17	2010-04-13	Taro Pharmaceutical Industries Limited	Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
WO2006046253A1 (en) *	2004-10-26	2006-05-04	Ipca Laboratories Limited	A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4695578A (en) *	1984-01-25	1987-09-22	Glaxo Group Limited	1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) *	1986-12-17	1987-01-28	Glaxo Group Ltd	Medicaments
SK6182003A3 (en) *	2000-10-30	2004-03-02	Teva Pharma	Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof

2002
- 2002-01-11 ES ES02703115T patent/ES2219201T1/es active Pending
- 2002-01-11 YU YU56103A patent/YU56103A/sh unknown
- 2002-01-11 MX MXPA03006215A patent/MXPA03006215A/es unknown
- 2002-01-11 HR HR20030631A patent/HRP20030631A2/hr not_active Application Discontinuation
- 2002-01-11 CZ CZ20032090A patent/CZ20032090A3/cs unknown
- 2002-01-11 JP JP2002556165A patent/JP2004526692A/ja active Pending
- 2002-01-11 SK SK989-2003A patent/SK9892003A3/sk not_active Application Discontinuation
- 2002-01-11 AU AU2002236753A patent/AU2002236753B2/en not_active Expired - Fee Related
- 2002-01-11 CN CNA2006101667179A patent/CN101045704A/zh active Pending
- 2002-01-11 PL PL02368837A patent/PL368837A1/xx not_active Application Discontinuation
- 2002-01-11 DE DE02703115T patent/DE02703115T1/de active Pending
- 2002-01-11 ZA ZA200305338A patent/ZA200305338B/xx unknown
- 2002-01-11 KR KR1020077010146A patent/KR20070054749A/ko not_active Ceased
- 2002-01-11 WO PCT/US2002/000853 patent/WO2002055492A2/en not_active Ceased
- 2002-01-11 EP EP02703115A patent/EP1355881A4/en not_active Withdrawn
- 2002-01-11 CA CA002433720A patent/CA2433720A1/en not_active Abandoned
- 2002-01-11 KR KR10-2003-7009221A patent/KR20030068583A/ko not_active Abandoned
- 2002-01-11 CN CNA028062019A patent/CN1496350A/zh active Pending
- 2002-01-11 TR TR2004/01460T patent/TR200401460T3/xx unknown
- 2002-01-11 IL IL15683502A patent/IL156835A0/xx unknown
- 2002-01-11 HU HU0400767A patent/HUP0400767A2/hu unknown
- 2002-01-11 KR KR1020067020069A patent/KR20060113792A/ko not_active Ceased
2003
- 2003-07-08 IS IS6869A patent/IS6869A/is unknown
- 2003-07-09 NO NO20033147A patent/NO20033147L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20033147L (no)	2003-09-02
ES2219201T1 (es)	2004-12-01
WO2002055492A3 (en)	2003-02-13
NO20033147D0 (no)	2003-07-09
PL368837A1 (en)	2005-04-04
HRP20030631A2 (en)	2005-06-30
HUP0400767A2 (hu)	2004-07-28
EP1355881A4 (en)	2004-03-31
CZ20032090A3 (cs)	2004-08-18
CN101045704A (zh)	2007-10-03
EP1355881A2 (en)	2003-10-29
IS6869A (is)	2003-07-08
TR200401460T3 (cs)	2004-08-23
IL156835A0 (en)	2004-02-08
JP2004526692A (ja)	2004-09-02
KR20060113792A (ko)	2006-11-02
WO2002055492A2 (en)	2002-07-18
KR20030068583A (ko)	2003-08-21
DE02703115T1 (de)	2004-10-21
YU56103A (sh)	2006-05-25
CA2433720A1 (en)	2002-07-18
MXPA03006215A (es)	2005-02-17
CN1496350A (zh)	2004-05-12
AU2002236753B2 (en)	2007-06-28
ZA200305338B (en)	2004-07-12
KR20070054749A (ko)	2007-05-29

Legal Events

Date	Code	Title	Description
2011-05-06	FC9A	Refused patent application

Publication	Publication Date	Title
CN101547892B (zh)	2014-08-20	制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
RS56103B1 (sr)	2017-10-31	Ublažavanje uticaja interferencije na uplink strani prilagođenjem snage predaje ćelije sa otvorenim pristupom
KR102718536B1 (ko)	2024-10-21	2-(5-메톡시이소크로만-1-일)-4,5-디하이드로-1h-이미다졸 및 이의 하이드로젠설페이트 염의 제조방법
CA2942301A1 (en)	2015-09-17	Clomiphene synthesis using a single solvent
CN110612291A (zh)	2019-12-24	2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
EP3015453A1 (en)	2016-05-04	Process for the preparation of Clomiphene
JPH02218682A (ja)	1990-08-31	エルゴリン誘導体
CZ20032090A3 (cs)	2004-08-18	Zdokonalený způsob přípravy čistého dihydrátu hydrochloridu ondansetronu
AU2002236753A1 (en)	2003-02-06	An improved process for preparing pure ondansetron hydrochloride dihydrate
US20020115707A1 (en)	2002-08-22	Process for preparing pure ondansetron hydrochloride dihydrate
KR101694262B1 (ko)	2017-01-10	실로도신의 결정형의 제조방법
RU2437878C2 (ru)	2011-12-27	Способы получения гетероциклических соединений
EP3015454A1 (en)	2016-05-04	Stable solid form of trans-Clomiphene citrate
CZ306203B6 (cs)	2016-09-29	Způsob syntézy lurasidonu
CN113754643A (zh)	2021-12-07	苯并吡喃衍生物的精制方法、其晶型及所述晶型的制备方法
KR960010353B1 (ko)	1996-07-30	티아디아졸 구아니딘 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2072510A1 (en)	2009-06-24	Crystalline form of azelastine
JP2020526573A (ja)	2020-08-31	純粋な５−ｈｔ６受容体アンタゴニストとしてのフルオロピペリジン化合物
EA011748B1 (ru)	2009-06-30	Способ получения рисперидона
EP2691387B1 (en)	2015-12-16	Process for the preparation of anhydrous aripiprazole crystal form ii
WO2023059903A1 (en)	2023-04-13	Synthesis of mavorixafor and intermediates thereof
KR101733084B1 (ko)	2017-05-08	실로도신의 결정형의 제조방법
EP1828141A1 (en)	2007-09-05	A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o
JP2023112012A (ja)	2023-08-10	デュアルヒスタミンｈ１及びヒスタミンｈ４受容体リガンドとしての新規ベンゾイミダゾール誘導体
JPH1067795A (ja)	1998-03-10	エリスロマイシン誘導体の製造法